Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 620

1.

Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.

Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJ, Lackner A, et al.

Brain. 1992 Oct;115 ( Pt 5):1249-73.

PMID:
1422788
3.

Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients.

Heyes MP, Brew BJ, Saito K, Quearry BJ, Price RW, Lee K, Bhalla RB, Der M, Markey SP.

J Neuroimmunol. 1992 Sep;40(1):71-80.

PMID:
1387655
4.

Relationship of neurologic status in macaques infected with the simian immunodeficiency virus to cerebrospinal fluid quinolinic acid and kynurenic acid.

Heyes MP, Jordan EK, Lee K, Saito K, Frank JA, Snoy PJ, Markey SP, Gravell M.

Brain Res. 1992 Jan 20;570(1-2):237-50.

PMID:
1535532
5.
6.
7.

Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse.

Saito K, Markey SP, Heyes MP.

Neuroscience. 1992 Nov;51(1):25-39.

PMID:
1465184
8.

Sustained increases in cerebrospinal fluid quinolinic acid concentrations in rhesus macaques (Macaca mulatta) naturally infected with simian retrovirus type-D.

Heyes MP, Gravell M, London WT, Eckhaus M, Vickers JH, Yergey JA, April M, Blackmore D, Markey SP.

Brain Res. 1990 Oct 29;531(1-2):148-58.

PMID:
1963097
9.

Kynurenine pathway metabolites in cerebrospinal fluid and serum in complex partial seizures.

Heyes MP, Saito K, Devinsky O, Nadi NS.

Epilepsia. 1994 Mar-Apr;35(2):251-7.

PMID:
8156942
10.
11.

Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques.

Heyes MP, Saito K, Lackner A, Wiley CA, Achim CL, Markey SP.

FASEB J. 1998 Jul;12(10):881-96.

PMID:
9657528
12.
13.

Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.

Sas K, Robotka H, Toldi J, VĂ©csei L.

J Neurol Sci. 2007 Jun 15;257(1-2):221-39. Epub 2007 Apr 25. Review.

PMID:
17462670
14.

Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid.

Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED.

J Neurochem. 1990 Oct;55(4):1327-39.

PMID:
2144582
15.

Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.

Harris CA, Miranda AF, Tanguay JJ, Boegman RJ, Beninger RJ, Jhamandas K.

Br J Pharmacol. 1998 May;124(2):391-9.

16.

Cerebrospinal fluid levels of kynurenine pathway metabolites in patients with eating disorders: relation to clinical and biochemical variable.

Demitrack MA, Heyes MP, Altemus M, Pigott TA, Gold PW.

Biol Psychiatry. 1995 Apr 15;37(8):512-20.

PMID:
7542489
17.

Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation.

Saito K, Nowak TS Jr, Suyama K, Quearry BJ, Saito M, Crowley JS, Markey SP, Heyes MP.

J Neurochem. 1993 Dec;61(6):2061-70.

PMID:
8245962
18.

Cerebral cortex and lung indoleamine-2,3-dioxygenase activity is increased in type-D retrovirus infected macaques.

Saito K, Lackner A, Markey SP, Heyes MP.

Brain Res. 1991 Feb 1;540(1-2):353-6.

PMID:
1647247
19.

Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children.

Heyes MP, Saito K, Milstien S, Schiff SJ.

J Neurol Sci. 1995 Nov;133(1-2):112-8.

PMID:
8583213
20.

Mechanism of increases in L-kynurenine and quinolinic acid in renal insufficiency.

Saito K, Fujigaki S, Heyes MP, Shibata K, Takemura M, Fujii H, Wada H, Noma A, Seishima M.

Am J Physiol Renal Physiol. 2000 Sep;279(3):F565-72.

Supplemental Content

Support Center